For research use only. Products are supplied strictly for laboratory and research purposes and are not intended for human consumption.
- Batch tested
- COA available
- Research use only
GLP-1 research
Semaglutide
Long-acting GLP-1 receptor agonist analogue and one of the most extensively referenced sequences in metabolic research.
Strength
Quantity
15% off your first order with code FIRST15
Bundle & save
Fast UK dispatch
Dispatch information shown at checkout
Tracked UK delivery
Available delivery options are shown at checkout
Protected shipping
Please see our Shipping Policy for full details.
Secure checkout
More ways to shop
Build a Box
Create a personalised research box from selected Amino Peppers compounds.
Verified test results
Every batch, independently documented.
Review the testing information and certificate available for the selected product batch.
ILS Laboratories
Certificate of Analysis
99.61%
Purity
- Lot
- APSEMA02
- Tested
- 12 Jun 2026
- Label claim
- 10mg vial
- Measured
- 10mg vial
Full QC panel
8 results reported
Appearance
Visual
White lyophilised cake
PassPurity
HPLC-UV, 214nm
99.61%
PassNet peptide content
Nitrogen determination
Conforms
PassIdentity
LC-MS (ESI+)
Confirmed
PassBacterial endotoxin
LAL kinetic chromogenic
< 0.05 EU/mg
PassHeavy metals
ICP-MS
Not detected
PassSterility
USP <71>
No growth
PassResidual solvents
GC headspace
Within limits
Pass
Every batch on record
View available certificates for previous product lots.
Product information
Research Detail
Research-grade Semaglutide peptide. A GLP-1 receptor agonist supplied as lyophilized powder for in vitro research. Third-party tested with Certificate of Analysis available.
What is Semaglutide?
Semaglutide is a synthetic analogue of human glucagon-like peptide-1 (GLP-1) studied primarily for its interaction with GLP-1 receptor pathways. In laboratory and preclinical research, it is examined for its role in glucose-dependent insulin secretion, gastric emptying models, appetite-related signalling, and broader metabolic regulation.
As a GLP-1 receptor agonist, semaglutide is designed to bind and activate GLP-1 receptors with high affinity. This makes it a valuable research compound for studying incretin biology, beta-cell function, energy-balance pathways, and endocrine signalling networks.
Semaglutide is supplied as a lyophilized powder for in vitro research. It is not intended for human or animal consumption.
Compound Profile
- Peptide Type
- Synthetic GLP-1 receptor agonist
- Molecular Weight
- ~4,113 g/mol
- Molecular Formula
- C187H291N45O59
- CAS Number
- 910463-68-2
- PubChem CID
- 56843331
- Research Category
- Incretin signalling, metabolic regulation
- Purity
- ≥99% (HPLC verified)
- Sequence
- Modified GLP-1 analogue (details available upon request)
Key Areas of Investigation
Semaglutide has been studied across metabolic, endocrine, cardiovascular, and cellular research models. The primary research interest centres on its high-affinity GLP-1 receptor activation and prolonged signalling duration.
These findings support semaglutide as a significant research tool for understanding GLP-1 biology, but they do not constitute evidence of therapeutic efficacy.
- Incretin Biology: GLP-1 receptor binding kinetics, signal transduction, and downstream intracellular cascades.
- Metabolic Research: Glucose homeostasis, insulin secretion models, glucagon regulation, and energy-balance pathways.
- Beta-Cell Function: Pancreatic beta-cell proliferation, survival signalling, and cellular response under metabolic stress.
- Gastrointestinal Models: Gastric emptying dynamics, nutrient absorption timing, and gut-brain axis communication.
- Appetite & Satiety: Central nervous system signalling, hypothalamic pathways, and food-intake regulation in preclinical models.
- Cardiometabolic Research: Lipid profiles, inflammatory markers, vascular endothelial function, and metabolic syndrome models.
Scientific references
- Lau J. et al. (2015) — Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide.
- Marso S.P. et al. (2016) — Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6).
- Sorli C. et al. (2017) — Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1).
- Wilding J.P.H. et al. (2021) — Once-weekly semaglutide in adults with overweight or obesity (STEP 1).
- Davies M. et al. (2021) — Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2).
- Kadowaki T. et al. (2023) — Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes (STEP 6).
- Lincoff A.M. et al. (2023) — Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT).
Technical specifications
Compound Information
Molecular profile
What is Semaglutide?
Semaglutide is a long-acting GLP-1 receptor agonist analogue and one of the most studied sequences in metabolic research. Every lot is independently tested and the certificate is published before the batch is released.
- Chemical class
- Acylated GLP-1 analogue
- CAS number
- 910463-68-2
- Molecular weight
- 4113.6 g/mol
- Amino acids
- 31
- Formula
- C187H291N45O59
Storage requirements
Stability information
- −20°C
Lyophilised powder
Sealed, protected from light. Stable 24 months.
- 2–8°C
Reconstituted
Use within 28 days of reconstitution.
- Ambient
In transit
Store sealed at 2–8°C, protected from light
Store sealed at 2–8°C, protected from light
Important research notice
Not for human, veterinary, or food use.
These products are supplied exclusively for laboratory and research purposes and are not intended for human consumption, diagnosis, treatment, cure, or prevention of disease.
Product information and research references are provided for educational and laboratory reference purposes.